Welcome to our dedicated page for OnKure Therapeutics SEC filings (Ticker: OKUR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The SEC filings page for OnKure Therapeutics, Inc. (OKUR) provides access to the company’s official regulatory disclosures as a clinical-stage biopharmaceutical issuer listed on the Nasdaq Global Market. These documents offer detailed information about its precision oncology programs, financial condition, and capital markets activities, complementing the high-level descriptions found in press releases.
Through its periodic reports on Forms 10-K and 10-Q, OnKure describes its focus on discovering and developing precision medicines that target biologically validated drivers of cancers underserved by current therapies. These filings expand on the company’s strategy around PI3Kα-targeted programs, including its lead candidate OKI-219 and its PI3Kα pan-mutant and other discovery-stage efforts, and include sections such as “Risk Factors” that outline scientific, clinical, regulatory, and financial risks.
Current reports on Form 8-K capture material events between periodic filings. For example, OnKure has filed 8-Ks to report quarterly financial results and to disclose entry into a sales agreement with Leerink Partners LLC for an at-the-market offering program of its Class A common stock. That agreement allows the company, subject to specified parameters and an effective shelf registration statement on Form S-3, to sell shares through Leerink Partners acting as sales agent, with compensation based on a percentage of gross proceeds.
On this page, users can review new and historical SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and registration statements such as Form S-3 referenced in the at-the-market program. Stock Titan’s tools apply AI-powered summaries to help explain the contents of lengthy filings, highlight key items like clinical development updates, capital raising arrangements, and risk disclosures, and make it easier to track how OnKure’s regulatory narrative evolves over time.
OnKure Therapeutics, Inc. reported the initial ownership of a major shareholder group led by AI Biotechnology LLC. The filing shows AI Biotechnology holds pre-funded warrants exercisable for 5,640,222 shares of Class A Common Stock at an exercise price of $0.0001 per share, plus 3,998,332 shares of Class A Common Stock.
The pre-funded warrants are subject to a Beneficial Ownership Blocker, limiting exercises so that AI Biotechnology’s beneficial ownership does not exceed 9.99% of outstanding Class A Common Stock, unless increased (with notice) up to but not above 19.99%. Access Industries entities and Len Blavatnik may be deemed indirect beneficial owners but disclaim beneficial ownership beyond their pecuniary interest.
AI Biotechnology LLC and affiliated Access Industries entities report beneficial ownership of 9,091,532 OnKure Therapeutics Class A shares, equal to 19.99% of the class. This includes 3,998,332 shares purchased directly and 5,093,200 shares issuable from pre-funded warrants.
On March 31, 2026, AI Biotechnology bought 3,998,332 shares at $4.15 per share and 5,640,222 pre-funded warrants at $4.1499 each, with a $0.0001 exercise price per share. The warrants are limited by a "Beneficial Ownership Blocker" that generally caps ownership at 9.99%, adjustable up to 19.99% with 61 days’ notice.
AI Biotechnology received a board designation right under a Securities Purchase Agreement, and Dr. Liam Ratcliffe of Access Industries now serves on OnKure’s board, conditioned on AI Biotechnology retaining at least 50% of the purchased securities. Registration rights provide for resale registration of the shares and warrant shares under a future SEC registration statement.
OnKure Therapeutics ownership filing: StepStone entities report shared beneficial ownership of 2,660,612 shares of Class A Common Stock, representing 6.6% of the class. The filing cites 40,395,478 shares outstanding as of April 1, 2026. The report attributes shared voting and dispositive power to StepStone-related partnerships and managers.
OnKure Therapeutics reports that Trails Edge-related filers beneficially own 2,409,638 shares (6.0% of Class A Common Stock) as of March 31, 2026. The filing states those shares are held directly by Trails Edge Biotechnology and that Trails Edge Capital and Ortav Yehudai may be deemed beneficial owners by virtue of management and voting discretion. Ownership percentages are calculated from approximately 40,387,201 shares issued and outstanding as of the Event Date, reflecting 13,673,565 shares outstanding as of March 11, 2026 and 26,713,636 shares issued in a private placement on March 31, 2026. The report is a joint Schedule 13G, and signatures and a Joint Filing Agreement are included.
OnKure Therapeutics, Inc. Schedule 13G reports that RA Capital-related reporting persons collectively beneficially own 4,038,715 shares of Class A common stock, representing 9.99% of the class under a beneficial ownership blocker. The Fund directly holds 3,998,332 shares and pre-funded warrants exercisable for up to 128,174 shares.
The filing states the 9.99% figure is calculated using 13,673,565 shares outstanding as of March 11, 2026, plus 26,713,636 shares issued in a private placement that closed March 31, 2026, and 40,383 shares issuable upon exercise of the Pre-Funded Warrants.
OnKure Therapeutics, Inc. reported that President and CEO Nicholas A. Saccomano received a grant of employee stock options covering 330,000 shares of Class A Common Stock. The options have an exercise price of $4.07 per share and expire on March 31, 2036.
According to the filing, Saccomano holds 330,000 options following this grant, all as direct holdings. The award vests over time, with 1/48th of the option shares vesting on May 1, 2026 and monthly thereafter, contingent on his continued service with the company.
OnKure Therapeutics, Inc. reported that Chief Financial Officer Jason A. Leverone received an employee stock option grant covering 110,000 shares of Class A common stock. The options have an exercise price of $4.07 per share and expire on March 31, 2036.
According to the vesting schedule, 1/48th of the shares subject to the option will vest on May 1, 2026 and monthly thereafter, as long as he continues as a service provider through each vesting date. Following this grant, he holds 110,000 stock options directly.
Hartley Dylan reported acquisition or exercise transactions in this Form 4 filing.
OnKure Therapeutics, Inc. reported that Chief Scientific Officer Dylan Hartley received a grant of 110,000 employee stock options to buy Class A Common Stock at $4.07 per share. These options expire on March 31, 2036 and function as equity-based compensation rather than an open-market share purchase.
According to the vesting terms, 1/48th of the options will vest on May 1, 2026 and then monthly thereafter, as long as Hartley continues as a service provider. After this grant, Hartley directly holds 110,000 options covering an equal number of Class A Common shares.
OnKure Therapeutics, Inc. Chief Medical Officer Samuel Agresta reported a compensation-related grant of 110,000 employee stock options to buy Class A Common Stock. The options carry an exercise price of $4.07 per share and expire on March 31, 2036.
According to the filing, 1/48th of the options will vest on May 1, 2026 and then monthly thereafter, as long as he continues as a service provider. Following this grant, he holds 110,000 derivative securities directly, with no open-market buying or selling reported.
OnKure Therapeutics director Liam Ratcliffe received a new stock option grant as part of compensation. The award covers 15,300 options to buy Class A common stock at an exercise price of $4.14 per share, expiring on March 30, 2036.
These options vest over time: 1/36 of the grant vests on April 30, 2026 and 1/36 on the last day of each following month, as long as he continues as a service provider. After this grant, he holds 15,300 stock options directly from this award.